Dyne Therapeutics, Inc. (DYN)
After hours:
| Previous Close | 26.00 |
| Open | 26.16 |
| Bid | 25.99 x 300 |
| Ask | 26.12 x 300 |
| Day's Range | 25.87 - 27.31 |
| 52 Week Range | 6.40 - 30.27 |
| Volume | |
| Avg. Volume | 1,262,638 |
| Market Cap | 2.248B |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -3.95 |
| Earnings Date | Aug 01, 2024 - Aug 05, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 37.75 |
GlobeNewswireDyne Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights
- Additional Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Anticipated in the Second Half of 2024 - WALTHAM, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today reported financial results for the first quarter of 2024 and recent business highlights. “I am excited about
- GlobeNewswire
Dyne Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed President and Chief Executive Officer
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that it has granted an inducement equity award to its newly appointed President and Chief Executive Officer, John G. Cox. The award was approved by the Compensation Committee of Dyne and was made as an inducement material to Mr. Cox’s acce
- GlobeNewswire
Dyne Therapeutics to Present at the Cantor Virtual Muscular Dystrophy Symposium
WALTHAM, Mass., March 27, 2024 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage muscle disease company focused on advancing innovative life-transforming therapeutics for people living with genetically driven diseases, today announced that Wildon Farwell, M.D., MPH, chief medical officer, and Oxana Beskrovnaya, Ph.D., chief scientific officer, are scheduled to participate in a fireside chat during the Cantor Virtual Muscular Dystrophy Symposium on Tuesday, April 2, 2024
